Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan
Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan
复制标题
DOI：
10.1007/s12185-008-0111-6
复制
发表时间：
2008-06
影响因子：
2.1
通讯作者：
Y. Nannya;H. Yokota;Yumiko Sato;G. Yamamoto;T. Asai;M. Ichikawa;Takuro Watanabe;K. Kumano;A. Hangaishi;Tsuyoshi Takahashi;S. Chiba;Y. Yatomi;M. Kurokawa
中科院分区：
文献类型：
--
作者：
Y. Nannya;H. Yokota;Yumiko Sato;G. Yamamoto;T. Asai;M. Ichikawa;Takuro Watanabe;K. Kumano;A. Hangaishi;Tsuyoshi Takahashi;S. Chiba;Y. Yatomi;M. Kurokawa
我们回顾性分析了在东京大学医院接受甲磺酸伊马替尼 (IM) 作为初始治疗的慢性粒细胞白血病 (CML) 患者的临床结果。在所有患者中，常规测量分子反应以及血液学和细胞遗传学反应。我们的队列显示出可观的结果，1 年内完全细胞遗传学缓解 (CR) 为 82%，5 年后为 97%。 29 名诊断时处于慢性期的患者的估计无进展生存率为 97%，估计 5 年 OS 为 92.4%。尽管在大约一半的病例中观察到因副作用而导致 IM 中断，但在所有病例中，中断只是暂时的。然而，对足够剂量的 IM（300 毫克/天或更多）表现出持续不耐受的患者表现出较差的分子反应。
We retrospectively analyzed the clinical outcome of chronic myelogenous leukemia (CML) patients who received imatinib mesylate (IM) as initial therapy at Tokyo University Hospital. In all patients, molecular response as well as hematological and cytogenetic response was measured routinely. Our cohort showed respectable outcome with complete cytogenetic response (CR) of 82% in 1 year, and 97% in 5 years. The estimated progression free survival of 29 patients who were in chronic phase at diagnosis was 97% and the estimated OS was 92.4% at 5 years. Although IM interruption due to side effects was observed in about half of the cases, the discontinuation was only temporary in all cases. However, patients who showed persistent intolerance with adequate dose of IM (300 mg/day or more) showed poor molecular response.